260 related articles for article (PubMed ID: 37346044)
21. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
22. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
23. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.
Angata T; Varki A
J Biol Chem; 2000 Jul; 275(29):22127-35. PubMed ID: 10801860
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.
Boelaars K; Rodriguez E; Huinen ZR; Liu C; Wang D; Springer BO; Olesek K; Goossens-Kruijssen L; van Ee T; Lindijer D; Tak W; de Haas A; Wehry L; Nugteren-Boogaard JP; Mikula A; de Winde CM; Mebius RE; Tuveson DA; Giovannetti E; Bijlsma MF; Wuhrer M; van Vliet SJ; van Kooyk Y
Commun Biol; 2024 Apr; 7(1):430. PubMed ID: 38594506
[TBL] [Abstract][Full Text] [Related]
25. Development of Effective Siglec-9 Antibodies Against Cancer.
Wang JHS; Jiang N; Jain A; Lim J
Curr Oncol Rep; 2023 Jan; 25(1):41-49. PubMed ID: 36445569
[TBL] [Abstract][Full Text] [Related]
26. The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.
Tsubata T
Int Immunol; 2023 Oct; 35(10):461-473. PubMed ID: 37504378
[TBL] [Abstract][Full Text] [Related]
27. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
28. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
29. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
[TBL] [Abstract][Full Text] [Related]
30. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
31. Exploring the Impact of Ketodeoxynonulosonic Acid in Host-Pathogen Interactions Using Uptake and Surface Display by Nontypeable Haemophilus influenzae.
Saha S; Coady A; Sasmal A; Kawanishi K; Choudhury B; Yu H; Sorensen RU; Inostroza J; Schoenhofen IC; Chen X; Münster-Kühnel A; Sato C; Kitajima K; Ram S; Nizet V; Varki A
mBio; 2021 Jan; 12(1):. PubMed ID: 33468699
[TBL] [Abstract][Full Text] [Related]
32. Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy.
Wu Q; Wei X; Chen F; Huang M; Zhang S; Zhu L; Zhou L; Yang C; Song Y
Angew Chem Int Ed Engl; 2023 Dec; 62(52):e202312609. PubMed ID: 37955317
[TBL] [Abstract][Full Text] [Related]
33. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer.
Wen R; Zhao H; Zhang D; Chiu CL; Brooks JD
Carbohydr Res; 2022 Sep; 519():108598. PubMed ID: 35691122
[TBL] [Abstract][Full Text] [Related]
34. The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
Coccimiglio M; Chiodo F; van Kooyk Y
Br J Dermatol; 2024 Apr; 190(5):627-635. PubMed ID: 38197441
[TBL] [Abstract][Full Text] [Related]
35. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters.
Angata T; Hingorani R; Varki NM; Varki A
J Biol Chem; 2001 Nov; 276(48):45128-36. PubMed ID: 11579105
[TBL] [Abstract][Full Text] [Related]
36. Sialic Acid-Siglec-E Interactions During
Mukherjee K; Khatua B; Mandal C
Front Immunol; 2020; 11():332. PubMed ID: 32184783
[No Abstract] [Full Text] [Related]
37. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
38. Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.
Siddiqui S; Schwarz F; Springer S; Khedri Z; Yu H; Deng L; Verhagen A; Naito-Matsui Y; Jiang W; Kim D; Zhou J; Ding B; Chen X; Varki N; Varki A
J Biol Chem; 2017 Jan; 292(3):1029-1037. PubMed ID: 27920204
[TBL] [Abstract][Full Text] [Related]
39. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E.
Redelinghuys P; Antonopoulos A; Liu Y; Campanero-Rhodes MA; McKenzie E; Haslam SM; Dell A; Feizi T; Crocker PR
J Biol Chem; 2011 Oct; 286(40):34522-32. PubMed ID: 21835922
[TBL] [Abstract][Full Text] [Related]
40. Flow Cytometry-Based Detection of Siglec Ligands.
Schmidt EN; Jung J; Macauley MS
Methods Mol Biol; 2023; 2657():181-193. PubMed ID: 37149531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
